Latest PSYC Newsletter Highlighted by Exclusive Interview with Johns Hopkins Professor
Latest PSYC Newsletter
Highlighted by Exclusive Interview with Johns Hopkins
LAS VEGAS, NV -- September 30,
2020 -- InvestorsHub NewsWire -- Global Trac Solutions, Inc.
PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce
that the second edition of its September Microdose Monthly
newsletter, released this morning to subscribers, is headlined by
an exclusive interview with Dr. Albert Garcia-Romeu, Assistant
Professor for Johns Hopkins Center for Psychedelic &
Since obtaining regulatory
approval in 2000 to reinitiate research with psychedelics, Johns
Hopkins has been at the forefront of some of the most
groundbreaking studies within the field of medicinal psychedelics.
Highlighting their research within this space is their 2006
publication on the safety and enduring positive effects of a single
dose of psilocybin that is considered a landmark study and one that
in many respects sparked renewed interest in psychedelic research
across the globe.
The interview, conducted by PSYC
CEO, David Flores, dives into the different psychedelic-related
clinical trials that Johns Hopkins is currently involved in,
including their ongoing studies related to researching the efficacy
of psilocybin for individuals who are tobacco or nicotine
dependent, as well as the science behind what makes certain
psychedelics so effective in treating specific mental health
Said Global Trac Solutions, CEO,
David Flores: “I am extremely appreciative of the time Dr.
Garcia-Romeu lent to us out of his busy schedule and for giving us
an opportunity to share some of the exciting developments that are
being examined at Johns Hopkins through their ongoing research with
psychedelics. As Psychedelic Spotlight and Microdose Monthly
continue to become a recognized and trusted source for news,
information, and education within the emerging community of
psychedelic medicine, keeping our audience informed on the many
different advancements and developments that are being achieved
within the science and research sector is of paramount importance.
I am delighted to share this interview with our audience and look
forward to continuing to develop and produce the thought-provoking,
quality-driven content that truly captures the momentum I believe
we are experiencing here in this industry.”
PSYC encourages those interested
in receiving exclusive content highlighting the emerging medicinal
psychedelic industry to subscribe today to its semi-monthly
newsletter by visiting www.psychedelicspotlight.com.
About Global Trac Solutions, Inc.
At Global Trac Solutions we are
integrating media, creativity, and technology to develop and deploy
thought-provoking ideas and solutions that are fostering and
transforming the approach to some of society’s most pressing
PSYC has expressed its intent and
commitment to positioning itself at the forefront of the
psychedelic revolution and as a resource center for discovering and
understanding the latest research and business opportunities
surrounding psychedelic inspired medicines. In conjunction with the
FDA’s more open-minded approach to psychedelic medicines, and as
several major U.S. cities continue to approve the decriminalization
of psilocybin, investors are speculating that the psychedelic boom
could be bigger than that of cannabis. PSYC is your source for
current investment related news specific to psychedelic medicines
and cutting-edge research improving overall health, moving this
sector into the mainstream.
We believe in a forward-thinking
approach that embraces groundbreaking new technology and
innovations and through the vision of business development we
intend to continue to evolve into these unchartered territories as
the industry leaders of the future. We truly are the right TRAC to
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. In some cases, you can
identify forward-looking statements by the following words:
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "ongoing," "plan," "potential," "predict,"
"project," "should," "will," "would," or the negative of these
terms or other comparable terminology, although not all
forward-looking statements contain these words. Forward-looking
statements are not a guarantee of future performance or results and
will not necessarily be accurate indications of the times at, or
by, which such performance or results will be achieved.
Forward-looking statements are based on information available at
the time the statements are made and involve known and unknown
risks, uncertainty and other factors, including the effect of
COVID-19, that may cause our results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by the forward-looking statements
in this press release. This press release should be considered in
light of all filings of the Company that are disclosed on the OTC
Disclaimer: Global Trac
Solutions, Inc. does not in any way encourage or condone the use,
purchase, sale or transfer of any illegal substances, nor do we
encourage or condone partaking in any unlawful activities. We
support a harm reduction approach for the purpose of education and
promoting individual and public safety. If you are choosing to use
psychedelic substances, please do so
Global Trac Solutions, Inc.